Join The Discussion

 

Group buys former Armour meatpacking site in Stockyards

The 16.8-acre site of the historic, former Armour meatpacking plant in Fort Worth’s Stockyards has changed hands, and its new owners aren’t saying anything about their plans. Chesapeake Land Development Co., which bought the site

read more >

Dallas-Fort Worth in top five commercial real estate markets in 2015

According to the Emerging Trends in Real Estate 2015 report, just co-published by PwC US and the Urban Land Institute (ULI), Dallas-Fort Worth ranks No. 5, with two other Texas cities, Houston and Austin ranking at No. 1 and 2 respectively. San Francisco ranks No. 3 and Denver No. 4.

read more >

Social House Fort Worth plans to open mid-November

Social House has leased 5,045 square feet at 2801-2873 W Seventh St. in Fort Worth, according to Xceligent Inc.

read more >

Hulen Pointe Shopping Center sold

Hulen Pointe Shopping Center, located in southwest Fort Worth on South Hulen Street one mile south of Hulen Mall, has been purchased by Addison-based Bo Avery with TriMarsh Properties for an undisclosed price.

read more >

Ski Grand Prairie? TCU, UTA grad helping bring snow to Metroplex

For Levi Davis last week may have been a career peak, in more ways than one.

read more >

Galderma gains distribution rights in U.S., Canada

Nestle S.A., Switzerland, a shareholder of Fort Worth-based Galderma Laboratories LP, has entered into an agreement with Valeant Pharmaceuticals International Inc. to become the distributor of several products in aesthetic dermatology.
Galderma will gain full rights to commercialize Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the United States and Canada.
Restylane, Perlane and Emervel are manufactured by Galderma and sold by its subsidiaries globally, except in the U.S. and Canada, where Valeant holds the distribution rights under terms of a pre-existing agreement with Medicis, which was acquired by Valeant in 2012. Through this transaction, Galderma will be able to further develop and supply these brands globally.


Galderma is acquiring Sculptra, owned by Valeant, and will commercialize it in the U.S. and Canada and select other markets around the world.
Dysport (branded Azzalure in Europe) is marketed by Galderma for aesthetic dermatology indications in many markets around the world. Valeant holds the distribution rights for the aesthetic dermatology indications under a similar agreement with Ipsen. The transaction will allow Galderma to distribute Dysport in the U.S. and Canada.


“The U.S. and Canada represent more than 50 percent of the fast growing global medical aesthetics market. This move secures Galderma’s continued ability to invest in product innovation, medical education, customer service and consumer awareness,” said Humberto C. Antunes, president and chief executive officer of Galderma worldwide.
This transaction is subject to regulatory clearance and other customary closing conditions. Credit Suisse acted as financial advisers, and Debevoise and Plimpton as legal advisers to Galderma.
In February 2014, Nestle announced that it had entered into an agreement with L’Oreal S.A. under which it will acquire the remaining 50 percent of Galderma owned by L’Oreal. The transaction between Nestle and Valeant is subject to regulatory clearance and certain other conditions, and is expected to close in July.

Betty Dillard
bdillard@bizpress.net
 

< back

Email   email
hide
Ebola
How worried are you about Ebola spreading?